WELLTOWER INC. (WELL): what the price requires
At today's price, WELLTOWER INC. (WELL) is priced for today's economics sustained for ~16.2 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/WELL
Headline
| Field | Value |
|---|---|
| Ticker | WELL |
| Company | WELLTOWER INC. |
| Current price | $234.37/sh |
| Composition | Seniors Housing Operating 81% / Triple-net 11% / Outpatient Medical 7% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | reit |
| Top-of-range FFO growth must hold for | 16.2y |
| Price-to-FFO | 52.6x |
| FFO yield | 1.9% |
Solve inputs: computed at a 8.9% cost of equity; growth searched up to the 15% ceiling; each 1pp moves the implied horizon ~3.9 years.
How unusual the bet is: extreme
| Reference | Value |
|---|---|
| vs own history | +0.73σ |
| cohort percentile (of 88 peers) | 100 |
| sustained it ~10 years at this level | 53% |
| implied end-window share | 1% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 10.81x | 3 | expensive |
| Earnings | 5.01x | 3 | expensive |
| Relative | 4.17x | 6 | expensive |
| Growth | 1.41x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.7%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $103.69 | 2.26x | yes | FCF base $3.2B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.7%, 7yr projection |
| DCF Exit Multiple | Growth | $166.48 | 1.41x | yes | Exit EV/EBITDA: 79.6x / 82.6x / 85.6x (bear / base = today's held flat / bull), 7yr |
| Relative Valuation | Relative | $144.31 | 1.62x | yes | P/E 40.74x (blended: static sector reference 35x + trailing (TTM) 54x), scenarios: 32.6x / 40.7x / 48.9x (bear / base = reference held flat / bull), EV/EBITDA 38.77x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $21.69 | 10.81x | yes | BV/sh $60.30, ROE (TTM) 3.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $13.22 | 17.73x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $173.13 | 1.35x | yes | Rev $11.8B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $51.96 | 4.51x | yes | FFO/share $4.33, growth 7% (input: historical FFO/share growth, 10y median), PEG=17.07 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | $9.91 | 23.65x | yes | BV $60.30 + 5yr PV of (ROE (TTM) 3.3% − Kₑ 9.3%) × BV; BV grows 2.2%/yr (excluded from median) |
| Graham Number | Asset | $76.65 | 3.06x | yes | √(22.5 × FFO/share $4.33 × BVPS $60.30) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $42.97 | 5.45x | yes | EBITDA $2.22B × sector EV/EBITDA 20.0x |
| FCF Yield | Earnings | $25.74 | 9.11x | yes | FCF $2952.7M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $2.54 | 92.27x | yes | SBC-adj FCF $1.39B (FCF $2.95B − SBC $1.56B) capitalized at Kₑ (excluded from median) |
| Ben Graham Formula | Earnings | $80.52 | 2.91x | yes | FFO/share $4.33 × (8.5 + 2×6.8%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $97.21 | 2.41x | yes | Revenue $11.77B × sector P/S 6.0x |
| PEG Fair Value | Relative | $44.45 | 5.27x | yes | FFO/share $4.33 × (PEG 1.5 × growth 6.8% (input: historical FFO/share growth, 10y median)) → PE 10.3x |
| Earnings Yield | Earnings | $46.81 | 5.01x | yes | FFO/share $4.33 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | $61.36 | 3.82x | yes | FFO/share $4.33 × 14.2x P/FFO (route cohort median, n=85); FFO $3.14B (FFO incl. D&A + impairments, FY2025, companyfacts), shares 726M |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt (REIT basis) | $13.2b |
| Net debt / FFO | 4.21x |
| Funds from operations (trailing) | $3.1b |
| Share count CAGR (dilution) | 12.7% |
| Burning cash | no |
REIT basis: leverage is read against funds from operations (FFO), not depreciation-gutted operating income. The header's implied growth runs on ADJUSTED FFO — FFO minus recurring maintenance capex — so the header's multiple and this leverage ratio use bases that differ by that capex; neither substitutes for the other. Interest expense is not separately reported in the cached statements, so fixed-charge coverage cannot be computed.
Bullet Takeaways
- Welltower owns senior housing, medical-office, and triple-net healthcare real estate, and its senior-housing operating portfolio is in a powerful occupancy-and-rate recovery, with that segment now driving 74% of same-store NOI, up from 57% a year ago.
- The recovery is producing real numbers: total same-store NOI grew 16.4% in the first quarter, led by 22.1% growth in senior housing on rising occupancy and 5% RevPOR gains, and management raised full-year normalized FFO guidance to $6.21 to $6.35 per share.
- The price embeds many years of that compounding continuing: it sits above every standard valuation lens, so the bet is that the senior-housing flywheel and a large external-acquisition pipeline keep running long enough to justify a price the static methods cannot reach.
Bull Case
The senior-housing cycle is turning Welltower's way, and the operating leverage in that turn is unusual. When occupancy rises in a senior-housing building, most of the new revenue falls to the bottom line, because the building's costs, staff, utilities, the physical plant, are already being carried. So a recovery in occupancy does not lift NOI a little; it lifts it a lot. That is exactly what is happening. The senior housing operating portfolio grew same-store NOI 22.1% in the first quarter, driving total portfolio same-store NOI up 16.4%, with that segment now 74% of same-store NOI versus 57% a year ago. The recovery is not a forecast; it is showing up in the prints.
The growth has two engines, and both are running. The first is organic: same-store senior-housing revenue rose 9.5% year over year, from roughly 370 basis points of occupancy gain and 5% growth in revenue per occupied room, with U.S. occupancy up nearly 400 basis points and Canada up about 300. Rising occupancy and rising rate at the same time is the best possible combination for a senior-housing landlord, because it means demand is strong enough to fill rooms and to charge more for them. The demographic wave behind it, an aging population needing housing and care, is the most predictable demand curve in real estate.
The second engine is external, and it is large. Welltower closed or put under contract $10.5 billion of investment activity year to date, including $3.3 billion completed in the first quarter and $7.2 billion closed or under contract after quarter-end. A REIT can only deploy capital at that scale if it can raise it cheaply, and Welltower can: its cost of equity sits low because the market values the platform highly, which lets it buy buildings and fund operators on terms competitors cannot match. That is a real, self-reinforcing advantage, and it is why the company keeps adding to the portfolio that is compounding fastest.
The balance sheet makes the growth durable rather than fragile, which is rare for a name priced this richly. Net debt to adjusted EBITDA was 2.73x with roughly $11.1 billion of liquidity, including $4.8 billion of cash and a fully available $6.25 billion revolver, leverage that improved from 3.03x at year-end. Conservative leverage on a portfolio compounding NOI at double digits means the growth is being funded prudently, and the dividend reflects the confidence: the board raised the quarterly payout 15% to $0.85 per share starting in the second quarter. The bull case is a demographic tailwind, two growth engines, and a balance sheet strong enough to keep feeding them.
Bear Case
No standard valuation method reaches this price, and that is the bear case stated as plainly as it can be. At $206.70 (as of June 27, 2026), Welltower trades at about 70 times the cash flow left after the recurring capital its buildings consume. Turn that around and the buyer is accepting an after-capital cash yield of roughly 1.4%, less than a short-term Treasury pays. A multiple that high is not a statement about this year's earnings. It is a bet that the current rate of compounding continues for a very long time, on the order of fifteen years, before the price is earned back from the cash the assets actually throw off. The whole question is whether a recovery can run that long.
Recoveries, by their nature, do not. The senior-housing surge driving the numbers is real, 22.1% NOI growth in that segment, occupancy up nearly 400 basis points in the U.S., but occupancy gains are a one-time refill of rooms that emptied earlier in the cycle, not a permanent growth rate. A building can go from low occupancy to high occupancy once; it cannot do it again. As occupancy approaches a normal stabilized level, the operating-leverage burst that produced 16.4% same-store NOI growth fades back toward the slower rate of rent increases alone. The price is extrapolating the explosive phase of the recovery across a span far longer than recovery phases last, and when the growth normalizes, a 70-times multiple does not stay at 70 times. It compresses, and at this price level the compression is what the holder would feel, not the underlying NOI.
The methods agree on the direction and the magnitude. Asset value, anchoring on the real estate and book equity, lands at a small fraction of the price; peer multiples and the earnings-power lens land well below it; and even the forward-growth methods, which explicitly credit next-period growth, fall short of the quote. When the optimistic, growth-crediting frame still cannot reach the price, the market is paying for something beyond what any disciplined method supports. That gap is not hidden value. It is the premium the recovery has to keep validating, quarter after quarter, with no margin for the cycle to turn.
The balance sheet is genuinely strong, and the bear has to concede it: net debt to adjusted EBITDA of 2.73x with about $11.1 billion of liquidity is conservative, so this is not a solvency story and the dividend is well covered. But low leverage does not protect a 70-times multiple from a growth slowdown; it only ensures the company survives one comfortably. There is one more cost the holder bears: funding $10.5 billion of acquisitions has come partly through issuing stock, and the share count has compounded at roughly 13% a year. Even if the deals are accretive, every share issued dilutes the existing holder's claim on that compounding NOI, so per-share growth has to clear an issuance toll the headline NOI figures do not show. The bet is not that Welltower is a bad company. It is that an extraordinary price requires an extraordinary duration of growth, and senior-housing recoveries have an expiration date the price does not.
Valuation
The honest place to start is the multiple itself. Against the cash flow left after the recurring capital its buildings consume, what a healthcare REIT calls AFFO, Welltower trades at roughly 70 times. That is the headline number, and it is an extraordinary one. Inverted, the price hands the buyer an after-capital cash yield of about 1.4%, below what a Treasury bill pays, which tells you immediately that the price is not being set by today's cash flow. It is being set by an expectation about how long today's growth lasts. On the engine's read, the multiple embeds something like fifteen years of the current compounding continuing before the price is paid back from the assets' own cash. The single most important fact about this quote is that duration assumption.
The gross figure refines down into that headline rather than softening it. Plain funds from operations, before the maintenance capital is netted out, still trades at about 46 times, so even the figure that ignores the capital the buildings consume is rich. AFFO is the more honest denominator, because senior-housing buildings genuinely require ongoing capital to stay competitive, and it is the AFFO multiple and the fifteen-year duration behind it that the price is actually leaning on. Framing this name on FFO alone would understate exactly how aggressive the bet is.
How far past the evidence the price sits is the most extreme of any normal operating REIT, and the pattern is unambiguous: no family of method reaches the price. Asset value, anchoring on the real estate and book equity, lands at a small fraction of it, so the buildings themselves are almost a free option on top of the operating growth. Peer multiples and the earnings-power lens land well below the price, and even the forward-growth methods, which are built to credit next-period growth, fall short. When the growth-crediting frame still cannot reach the quote, the price is paying for durability that the static methods structurally cannot price. That spread is the premium, and it is large.
The concrete "what has to be true" is the senior-housing flywheel running for the better part of two decades. The first quarter delivered 22.1% NOI growth in that segment on 9.5% revenue growth, built from nearly 400 basis points of U.S. occupancy gain and 5% RevPOR growth, and management raised full-year normalized FFO guidance to $6.21 to $6.35 per share. The price requires that pace, or something near it, to persist far longer than recovery phases usually do. Solvency, unusually, is a strength rather than a risk: net debt of about $13.2 billion sits a little over four times FFO, net debt to adjusted EBITDA was 2.73x, and liquidity is roughly $11.1 billion, so the growth is being funded prudently even as the share count compounds near 13% a year to feed $10.5 billion of acquisitions. The sell-side average target near $227 sits above today's quote with a Buy consensus, which means the street credits even more duration of the recovery than the current price does, the gap between the two measuring how much of the senior-housing wave each side is willing to underwrite.
Catalysts
The next scheduled event is the second-quarter print, with results due after the close on July 27 2026 and the call on July 28. The line to watch is senior-housing same-store NOI and the occupancy and RevPOR behind it. The first quarter set a high bar: 22.1% NOI growth in that segment, total same-store NOI up 16.4%, U.S. occupancy up nearly 400 basis points, and RevPOR up 5%. Because the price embeds many years of this compounding, any deceleration in occupancy or rate, or any sign the recovery is stabilizing, would matter more here than at a moderately priced REIT.
The acquisition pipeline is the second driver and it is unusually visible. Welltower closed or put under contract $10.5 billion of investment activity year to date, with $7.2 billion of it closed or under contract after quarter-end. Watching that capital convert into NOI, and at what yields, is the external-growth half of the thesis; large, accretive deals at attractive cap rates extend the runway, while pricing that compresses returns would not.
Management already raised full-year normalized FFO guidance to $6.21 to $6.35 per share and lifted the dividend 15% to a $0.85 quarterly rate, both signals of confidence the next print will test. On the sell-side, targets have moved higher, with an average near $227 and a Buy consensus, and individual notes ranging up toward the low $270s and a Scotiabank Outperform at $232. The street is more bullish than the current quote, so the catalysts are operational: the occupancy and RevPOR trajectory and the pace of capital deployment, not a rating change.
Peer Cohorts (Per Segment, With Filing Citations)
Seniors Housing Operating (reported)
- VTR (Ventas, Inc.)
- (no filing in the citation store)
- AHR (American Healthcare REIT, Inc.)
- (no filing in the citation store)
- NHI (National Health Investors, Inc.)
- (no filing in the citation store)
- SBRA (SABRA HEALTH CARE REIT, INC.)
- (no filing in the citation store)
- LTC (LTC PROPERTIES INC)
- (no filing in the citation store)
Triple-net (reported)
- OHI (OMEGA HEALTHCARE INVESTORS, INC.)
- (no filing in the citation store)
- SBRA (SABRA HEALTH CARE REIT, INC.)
- (no filing in the citation store)
- LTC (LTC PROPERTIES INC)
- (no filing in the citation store)
- NHI (National Health Investors, Inc.)
- (no filing in the citation store)
- VTR (Ventas, Inc.)
- (no filing in the citation store)
Outpatient Medical (reported)
- DOC (Healthpeak Properties, Inc.)
- (no filing in the citation store)
- HR (HEALTHCARE REALTY TRUST INCORPORATED)
- (no filing in the citation store)
- ARE (ALEXANDRIA REAL ESTATE EQUITIES, INC.)
- (no filing in the citation store)
- VTR (Ventas, Inc.)
- (no filing in the citation store)
- AHR (American Healthcare REIT, Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Welltower Q1 2026 results, April 28 2026 · Welltower dividend declaration, April 2026 · stockanalysis.com analyst data; MarketBeat consensus, 2026 · Welltower earnings announcement, 2026 · Welltower Q1 2026 results and dividend declaration, April 2026 · stockanalysis.com analyst data; Scotiabank note, 2026